Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Glioblastoma is the most aggressive cancer among primary brain tumours. As with other cancers, the incidence of glioblastoma is increasing; despite modern therapies, the overall mean survival of patients post-diagnosis averages around 16 months, a figure that has not changed in many years. Cannabige...

Full description

Bibliographic Details
Main Authors: Tamara T. Lah, Metka Novak, Milagros A. Pena Almidon, Oliviero Marinelli, Barbara Žvar Baškovič, Bernarda Majc, Mateja Mlinar, Roman Bošnjak, Barbara Breznik, Roby Zomer, Massimo Nabissi
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cells
Subjects:
apoptosis
cannabinoids
cannabigerol
cannabidiol
delta-9-tetrahydrocannabinol
glioblastoma
Online Access:https://www.mdpi.com/2073-4409/10/2/340

Internet

https://www.mdpi.com/2073-4409/10/2/340

Similar Items